PL2089031T3 - Redukowanie nadwagi lub otyłości - Google Patents

Redukowanie nadwagi lub otyłości

Info

Publication number
PL2089031T3
PL2089031T3 PL07766498T PL07766498T PL2089031T3 PL 2089031 T3 PL2089031 T3 PL 2089031T3 PL 07766498 T PL07766498 T PL 07766498T PL 07766498 T PL07766498 T PL 07766498T PL 2089031 T3 PL2089031 T3 PL 2089031T3
Authority
PL
Poland
Prior art keywords
reduction
overweight
obesity
weight gain
bgp
Prior art date
Application number
PL07766498T
Other languages
English (en)
Inventor
Nagy Péter Literati
Zoltán Szilvassy
Kálmán Tory
László Vigh
Kálmán Takacs
József Mandl
Balázs Sümegi
Sándor Bernath
Attila Kolonics
Gábor Balogh
János Egri
Original Assignee
N Gene Res Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Laboratories Inc filed Critical N Gene Res Laboratories Inc
Publication of PL2089031T3 publication Critical patent/PL2089031T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Pyridine Compounds (AREA)
PL07766498T 2006-11-02 2007-07-23 Redukowanie nadwagi lub otyłości PL2089031T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85611706P 2006-11-02 2006-11-02
US11/687,945 US7763601B2 (en) 2006-11-02 2007-03-19 Prevention and treatment of obesity
EP07766498A EP2089031B1 (en) 2006-11-02 2007-07-23 Reduction of overweight or obesity
PCT/HU2007/000066 WO2008053256A1 (en) 2006-11-02 2007-07-23 Reduction of overweight or obesity

Publications (1)

Publication Number Publication Date
PL2089031T3 true PL2089031T3 (pl) 2011-05-31

Family

ID=38592002

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07766498T PL2089031T3 (pl) 2006-11-02 2007-07-23 Redukowanie nadwagi lub otyłości

Country Status (19)

Country Link
US (1) US7763601B2 (pl)
EP (1) EP2089031B1 (pl)
JP (1) JP2010509199A (pl)
KR (1) KR20090082442A (pl)
AT (1) ATE489090T1 (pl)
AU (1) AU2007315931A1 (pl)
BR (1) BRPI0717867A2 (pl)
CA (1) CA2668382A1 (pl)
DE (1) DE602007010819D1 (pl)
DK (1) DK2089031T3 (pl)
HR (1) HRP20110023T1 (pl)
IL (1) IL198296A (pl)
MX (1) MX2009004538A (pl)
NO (1) NO20092025L (pl)
PL (1) PL2089031T3 (pl)
PT (1) PT2089031E (pl)
RU (1) RU2443417C2 (pl)
SI (1) SI2089031T1 (pl)
WO (1) WO2008053256A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
DE102020003608A1 (de) * 2020-06-17 2021-12-23 Bernd Clement Hemmstoffe von mARC1 zur Behandlung von Krankheiten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) * 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4287220A (en) * 1980-02-19 1981-09-01 Frito-Lay, Inc. Hull containing compositions
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
US6458371B1 (en) * 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) * 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
WO2000007580A2 (en) 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
EP1408966B1 (en) 2001-07-17 2008-02-20 N-Gene Research Laboratories Inc. Synergistic pharmaceutical combinations for the prevention or treatment of diabetes
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en) 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途

Also Published As

Publication number Publication date
US7763601B2 (en) 2010-07-27
RU2009119567A (ru) 2010-12-10
JP2010509199A (ja) 2010-03-25
EP2089031A1 (en) 2009-08-19
EP2089031B1 (en) 2010-11-24
BRPI0717867A2 (pt) 2013-10-29
SI2089031T1 (sl) 2011-04-29
ATE489090T1 (de) 2010-12-15
US20080108673A1 (en) 2008-05-08
DE602007010819D1 (de) 2011-01-05
KR20090082442A (ko) 2009-07-30
AU2007315931A1 (en) 2008-05-08
PT2089031E (pt) 2011-02-24
MX2009004538A (es) 2009-05-22
HK1131737A1 (en) 2010-02-05
IL198296A0 (en) 2010-02-17
HRP20110023T1 (hr) 2011-04-30
IL198296A (en) 2011-09-27
WO2008053256A1 (en) 2008-05-08
DK2089031T3 (da) 2011-02-14
NO20092025L (no) 2009-06-02
CA2668382A1 (en) 2008-05-08
RU2443417C2 (ru) 2012-02-27

Similar Documents

Publication Publication Date Title
IL198296A0 (en) Reduction of overweight or obesity
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2008142055A3 (en) Antiviral agents
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
WO2010066629A3 (en) Novel azaindoles
EP1874317A4 (en) PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES IN THE TREATMENT OF OBESITY
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TNSN08191A1 (en) Kinase inhibitors
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
SI2540319T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo
IL198294A0 (en) A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
WO2008054793A3 (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
IL185457A0 (en) 5-phenyl-pentanoic acid derivatives as metrix metalloproteinase inhibitors for the treatment of asthma and other diseases
TN2012000105A1 (en) Spirolactam derivatives and uses of same
SG170795A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007112913A3 (en) Benzimidazole derivatives
GB2421442B (en) Tidal gas resuscitation monitor
WO2007120848A3 (en) Devices, systems and methods using magnetic force systems in the tongue
IL181267A0 (en) Vla-4 antagonists
WO2011058336A3 (en) Tablet comprising gum arabic
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
PT1922415E (pt) Uso de rd9 e is6110 como ácidos nucleicos-alvo para o diagnóstico da tuberculose, e fornecimento de alvos is6110 e rd9 compatíveis com uma utilização multiplex
ZA200805703B (en) Preparation of pharmaceutical salts of 3-0-(3&#39;,3&#39;-dimethyl-succinyl) betulinic acid